HIMSS 2017: How digital tech can boost social determinants of health

The social determinants of health (SDOH) are conditions such as geographic location, genetics, diet and education that can impact the health of population groups. In a session at HIMSS 2017 in Orlando, Jane Sarasohn-Kahn, MA, MHSA, discussed how technological advancements can engage consumers and providers to address these SDOH that can improve or diminish health risks.

Sarasohn-Kahn explained that the integration of health IT with SDOH carries enormous potential in improving quality social care, versus simply just healthcare. The U.S. places greater emphasis on treating health than providing social care programs, Sarasohn-Kahn argued. Such prioritization has led to the U.S. falling behind in addressing SDOH when treating its population. The U.S. has entered a cycle of treating—rather than preventing—ill health. Taking examples of social health IT, Sarasohn-Kahn showed how the U.S. can begin to invest in social care.

Still, implementation remains blocked by barriers including a lack of knowledge, the slow advancement of best practices and a difficulty in sharing data across platforms. But platforms have entered the market to address these obstacles. These platforms enable the sharing of data, not only for health data purposes, but for community resources as well. For example, Purplebinder, a self-described “one-stop shop to address SDOH," gives communities access to information regarding food pantries, housing and substance abuse centers, which have decreased emergency room visits by 60 percent.

These community resources address every SDOH and pave the way for new innovations. While more hurdles still must be cleared, according to Sarasohn-Kahn, social health will ultimately be as important as treating high blood pressure.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.